ImmunoGen, Inc. (NASDAQ:IMGN)

CAPS Rating: 4 out of 5

The Company develops antibody-based anticancer therapeutics.

Results 1 - 20 of 43 : 1 2 3 Next »

Recs

0
Member Avatar hba24 (94.27) Submitted: 12/19/2014 2:24:49 PM : Outperform Start Price: $6.35 IMGN Score: -3.78

Dip provides a good entry point.

Recs

0
Member Avatar Amoeba17 (51.21) Submitted: 12/19/2014 11:45:39 AM : Underperform Start Price: $6.13 IMGN Score: +0.52

Took a big hit this morning with poor clinical trial results. Other trials are still underway but I suspect some investors will get spooked sending the stock price down.

Recs

0
Member Avatar benyboy (< 20) Submitted: 9/8/2014 11:56:51 PM : Outperform Start Price: $11.64 IMGN Score: -50.56

see a lot of value here, said Cramer. At current levels I'm a buyer

Recs

0
Member Avatar asilverp (60.28) Submitted: 8/29/2014 11:29:20 PM : Underperform Start Price: $12.02 IMGN Score: +51.93

High valuations and low relative strength. Will probably continue to slide.

Recs

0
Member Avatar SmartAce (99.88) Submitted: 5/20/2014 2:44:20 PM : Outperform Start Price: $11.45 IMGN Score: -56.88

oversold

Recs

0
Member Avatar gkm2864 (< 20) Submitted: 2/6/2014 3:58:36 PM : Outperform Start Price: $14.33 IMGN Score: -73.72

Big pipeline of potentially profitable new drugs.

Recs

0
Member Avatar jb2un (21.92) Submitted: 1/3/2014 4:29:58 PM : Outperform Start Price: $14.63 IMGN Score: -71.15

I am hoping for a big year with clinical trials and partnered products.

Recs

1
Member Avatar zzlangerhans (99.85) Submitted: 12/1/2013 2:21:01 AM : Outperform Start Price: $13.75 IMGN Score: -69.84

I ended my underperform on ImmunoGen a little prematurely in order to align my CAPS picks with the zzporte portfolio, so I missed my long-awaited catharsis of the sudden discontinuation of the NORTH trial for futility. Nevertheless, the failure did provide me a better entry for this green thumb that supports our real life position of 650 shares at a cost basis of 16. Kadcyla royalties remain mostly theoretical but European approval of Kadcyla, positive results of TH3RESA, and upcoming data from the MARIANNE trial of Kadcyla as first line treatment in HER-2 positive breast cancer should help Immunogen with the investors that like to bank on potnetial.

Recs

0
Member Avatar TerryHoodSr (65.20) Submitted: 10/30/2013 2:45:53 PM : Outperform Start Price: $13.83 IMGN Score: -73.15

1yr sales grwth 117% ,3yr sales grwth 33%

Recs

0
Member Avatar Sagemanx (56.04) Submitted: 8/15/2013 3:34:11 AM : Outperform Start Price: $16.61 IMGN Score: -86.58

UBS must be trying to drive this down, don't fall for it...

Recs

0
Member Avatar DrLinks (< 20) Submitted: 7/20/2013 4:27:53 PM : Outperform Start Price: $18.84 IMGN Score: -89.47

With its AntiSense technology, this is a Biotech winner LT!

Recs

0
Member Avatar ElRemaro (41.57) Submitted: 3/31/2013 10:00:34 AM : Outperform Start Price: $16.02 IMGN Score: -93.75

TMFUltraLong

Recs

0
Member Avatar bychen (< 20) Submitted: 1/22/2013 11:11:45 AM : Outperform Start Price: $15.68 IMGN Score: -100.34

The technology is bearing fruit and could be applied to multiple cancers.

Recs

0
Member Avatar Agabone (< 20) Submitted: 1/14/2013 8:22:35 PM : Outperform Start Price: $14.65 IMGN Score: -99.47

Immunogen's proprietary TAP technology is licensedto Genentech for their groundbreaking drug for HER2-positive metastatic breast cancer. This drug looks all set for approval within the very near future and its clinical trials data show significant increases in overall survival. This is a treatment that has the potential to transform the eway we treat breast cancer and has implications for other tumor types, too. When the drug is approved, the money will start to roll in for Immunogen.

Recs

0
Member Avatar genedom (98.11) Submitted: 10/30/2012 2:18:55 AM : Outperform Start Price: $11.52 IMGN Score: -92.55

Value at this price.

Recs

0
Member Avatar HIGHG33K (92.26) Submitted: 9/13/2012 11:22:15 AM : Outperform Start Price: $14.56 IMGN Score: -100.93

Undervalued comparing with SGEN

Recs

0
Member Avatar etbean (47.84) Submitted: 8/7/2012 4:20:44 PM : Outperform Start Price: $13.10 IMGN Score: -101.03

just watching it go down. Will buy around 8$

Recs

0
Member Avatar talia123 (35.45) Submitted: 3/30/2012 9:44:05 AM : Outperform Start Price: $15.06 IMGN Score: -106.29

It only take 1 good drug

Recs

0
Member Avatar kmv98finance (38.51) Submitted: 1/31/2012 12:56:29 PM : Outperform Start Price: $14.14 IMGN Score: -114.43

This is a great company based on a solid science foundation. It's platform is proving to work. Not only did TDM1 have phenomenal phase 2 results, but its partnerships with other companies are also doing very well. This indicates a lot more future value when these products get through development. I see this as a buy and anticipate the company will be acquired someday...hopefully by Roche.

Recs

0
Member Avatar thomluc3 (< 20) Submitted: 10/1/2011 3:36:01 PM : Outperform Start Price: $10.83 IMGN Score: -127.17

Good approach to cancer therapy. A step away from traditional chemotherapy. Any breakthrough in adenocarcinoma tumor therapy will lead to application for prostate carcinoma. We have not had any real therapeutic breakthrough in a long time. The tools are now in the workshop!

Results 1 - 20 of 43 : 1 2 3 Next »

Featured Broker Partners


Advertisement